<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-133116" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Wet Age-Related Macular Degeneration (AMD)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hobbs</surname>
            <given-names>Samuel D.</given-names>
          </name>
          <aff>Wilford Hall Ambulatory Surgical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pierce</surname>
            <given-names>Kristine</given-names>
          </name>
          <aff>Wilford Hall Ambulatory Surgical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samuel Hobbs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristine Pierce declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-133116.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Wet (exudative or neovascular) age-related macular degeneration is the most common cause of visual impairment among older patients in developed countries. Approximately 10% of patients with age-related macular degeneration develop choroidal neovascularization, which is the hallmark of wet age-related macular degeneration. Vascular endothelial growth factor plays a critical role in the development of choroidal neovascularization,&#x000a0;leading to complications such as bleeding under the retina, retinal pigment epithelium detachment or atrophy, hard exudate deposition, or subretinal or subretinal pigment epithelium&#x000a0;fluid accumulation with associated vision loss.</p>
        <p>Wet age-related macular degeneration diagnosis relies on clinical examination and imaging techniques. Fundus examination&#x000a0;may show retinal hemorrhages or exudates, whereas optical coherence tomography offers detailed images of retinal structure and fluid. Fluorescein angiography helps confirm neovascularization by visualizing dye leakage from retinal blood vessels.</p>
        <p>Anti-vascular endothelial growth factor therapy is the primary treatment, with intravitreal injections of agents such as ranibizumab or aflibercept reducing abnormal blood vessel growth and fluid leakage. Depending on the case, laser photocoagulation and photodynamic therapy may also be used. Regular monitoring is crucial for assessing treatment effectiveness and making the necessary adjustments.</p>
        <p>This activity for healthcare professionals is designed to enhance learners' competence in evaluating and managing wet age-related macular degeneration. Participants gain a deeper understanding of the condition's risk factors, pathogenesis, clinical presentation, and recommended evaluation and management strategies. Emphasis is placed on the role of the interprofessional team in improving patient care. Enhanced proficiency enables learners to work effectively and confidently within an interprofessional team caring for patients with wet age-related macular degeneration.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine the risk factors for developing wet age-related macular degeneration.</p></list-item><list-item><p>Identify the typical presentation of a patient with wet age-related macular degeneration.</p></list-item><list-item><p>Implement current evidence-based treatment options for wet age-related macular degeneration.</p></list-item><list-item><p>Collaborate with the interprofessional team to educate, treat, and monitor patients with wet age-related macular degeneration and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=133116&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=133116">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-133116.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The retina is a layer of neurosensory tissue in the eye that converts light into neural signals, which the brain interprets as images. The macula is the part of the retina with the highest concentration of cones essential&#x000a0;for&#x000a0;central vision.<xref ref-type="bibr" rid="article-133116.r1">[1]</xref>&#x000a0;Wet age-related macular degeneration (AMD), also known as exudative or neovascular AMD, primarily affects the macula and is the most common cause of central visual impairment and blindness among older individuals in developed countries.<xref ref-type="bibr" rid="article-133116.r2">[2]</xref>&#x000a0;</p>
        <p>Vascular endothelial growth factor (VEGF) drives the development of choroidal neovascularization (CNV), where new vessels grow under or through the retinal pigment epithelium (RPE),&#x000a0;often through breaks in the Bruch membrane. (see <bold>Image</bold>.&#x000a0;Peripapillary&#x000a0;Choroidal&#x000a0;Neovascular&#x000a0;Membrane).<xref ref-type="bibr" rid="article-133116.r3">[3]</xref>&#x000a0;Regular administration of intravitreal anti-VEGF medications may prevent blindness in most patients with wet AMD.<xref ref-type="bibr" rid="article-133116.r4">[4]</xref> In the absence of such treatment, patients experience severe, irreversible vision loss.<xref ref-type="bibr" rid="article-133116.r5">[5]</xref></p>
      </sec>
      <sec id="article-133116.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>AMD&#x000a0;is a multifactorial disease, and numerous risk factors have been identified. The possible risk factors include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Older age</p>
          </list-item>
          <list-item>
            <p>Elevated total serum cholesterol</p>
          </list-item>
          <list-item>
            <p>Micronutrient deficiency</p>
          </list-item>
          <list-item>
            <p>Smoking</p>
          </list-item>
          <list-item>
            <p>Family history</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Cardiovascular disease</p>
          </list-item>
          <list-item>
            <p>Exposure to&#x000a0;visible light&#x000a0;<xref ref-type="bibr" rid="article-133116.r6">[6]</xref><xref ref-type="bibr" rid="article-133116.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>A genetic predisposition to AMD is evident, as at least 34 genetic loci and 52 gene variants are associated with the disease.<xref ref-type="bibr" rid="article-133116.r8">[8]</xref>&#x000a0;Many findings indicate that inflammation plays a key role in the pathogenesis of wet AMD. Most notably, polymorphisms of complement factor H, which normally inhibits the alternative complement pathway, are among the best-known mutations in AMD, suggesting the important role of complement activation in its development.<xref ref-type="bibr" rid="article-133116.r9">[9]</xref><xref ref-type="bibr" rid="article-133116.r10">[10]</xref></p>
      </sec>
      <sec id="article-133116.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In 2015, AMD was the third most common cause of moderate-to-severe visual impairment worldwide. The global prevalence of AMD among individuals aged 45&#x000a0;to 85 was 8.7%, with a prevalence of 0.4%&#x000a0;for advanced AMD.<xref ref-type="bibr" rid="article-133116.r11">[11]</xref> Early AMD is more common among individuals of European ancestry compared to Asians, and AMD of any stage is less common in&#x000a0;individuals of African origin.<xref ref-type="bibr" rid="article-133116.r12">[12]</xref>&#x000a0;The global prevalence of any AMD stage is predicted to increase from 196 million people in 2020 to 288 million by 2040.<xref ref-type="bibr" rid="article-133116.r11">[11]</xref></p>
        <p>Approximately 10% to 15% of patients with AMD develop neovascular disease.<xref ref-type="bibr" rid="article-133116.r13">[13]</xref> In the absence of anti-VEGF therapy, around 79% to 90% of affected eyes eventually&#x000a0;become legally blind&#x000a0;due to complications from neovascularization.<xref ref-type="bibr" rid="article-133116.r14">[14]</xref>]</p>
      </sec>
      <sec id="article-133116.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>AMD is differentiated from early or dry AMD by the presence of CNV, where new blood vessels from the choroid penetrate through the Bruch membrane and proliferate either between the Bruch membrane and the RPE or in the subretinal space.<xref ref-type="bibr" rid="article-133116.r15">[15]</xref>&#x000a0;Various factors contribute to the development of CNV and vision loss in patients with wet AMD.<xref ref-type="bibr" rid="article-133116.r16">[16]</xref>&#x000a0;These factors include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>VEGF accumulation, particularly the VEGF-165 isoform</p>
          </list-item>
          <list-item>
            <p>Growth of&#x000a0;new blood vessels with the proliferation of fibrous tissue</p>
          </list-item>
          <list-item>
            <p>Leakage of fluid, proteins, and lipids from the new vessels</p>
          </list-item>
          <list-item>
            <p>Hemorrhage from the fragile new vessels</p>
          </list-item>
          <list-item>
            <p>Fibrovascular scar formation, with the death of the neurosensory retina and vision loss</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133116.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Dr. John Donald MacIntyre Gass classified CNVs into 2 types based on their anatomic histopathological location:</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 1 CNV is located below the RPE. This type is typically observed&#x000a0;in AMD and correlates with occult CNV in fluorescein angiography.<xref ref-type="bibr" rid="article-133116.r17">[17]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Type 2 CNV is subretinal, occurring between the retina and the RPE. This type is typically noted with CNVs secondary to presumed ocular histoplasmosis syndrome.<xref ref-type="bibr" rid="article-133116.r18">[18]</xref>&#x000a0;Classic CNV in wet AMD is a type 2 CNV.</p>
          </list-item>
        </list>
        <p>Type 3&#x000a0;neovascularization (retinal angiomatous proliferation or RAP) starts intraretinally and then reaches the subretinal or sub-RPE area.<xref ref-type="bibr" rid="article-133116.r19">[19]</xref><xref ref-type="bibr" rid="article-133116.r20">[20]</xref>&#x000a0;The origin of neovascularization may vary and may not start in the choroid itself. Thus, according to the <italic toggle="yes">Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration</italic>, these subtypes are currently included under the broad term macular neovascularization (MNV)<italic toggle="yes">.</italic></p>
        <p>MNV is further classified into&#x000a0;3 types based on multimodal imaging characteristics, including optical coherence tomography (OCT), OCT angiography, fluorescein angiography, and indocyanine green angiography (ICGA).</p>
        <list list-type="bullet">
          <list-item>
            <p>In type 1 MNV, the neovascularization process starts at the choriocapillaris and grows into and within the sub-RPE space, leading to different types of pigment epithelial detachment (PED) (see <bold>Image</bold>.&#x000a0;Retinal&#x000a0;Pigment&#x000a0;Epithelial&#x000a0;Detachment).&#x000a0;Polypoidal choroidal vasculopathy (PCV) is a subtype of type 1 MNV.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Type 2 MNV originates in the choroid and passes through the Bruch membrane and RPE to reach the subretinal space, where it proliferates.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In type 3 MNV, the new vessel starts&#x000a0;from the retinal circulation, typically in the deep retinal capillary plexus, and then grows toward the outer retina.<xref ref-type="bibr" rid="article-133116.r21">[21]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133116.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with wet AMD typically report visual distortion or blurring of central vision, particularly affecting their near vision. Some may experience metamorphopsia, micropsia, or scotoma, whereas others might report no symptoms or only vague vision complaints.<xref ref-type="bibr" rid="article-133116.r22">[22]</xref></p>
        <p>Upon examination, patients often show decreased best-corrected visual acuity. An Amsler grid&#x000a0;test may reveal areas of central or paracentral scotoma or visual distortion (see <bold>Image</bold>. Amsler Grid). The ophthalmic examination of the front part of the eye usually shows normal results. Age-related cataracts or pseudophakia may be noted. AMD-related&#x000a0;CNV has several different appearances on the dilated funduscopic examination (see <bold>Image</bold>.&#x000a0;Age-Related&#x000a0;Macular&#x000a0;Degeneration on Funduscopy).<xref ref-type="bibr" rid="article-133116.r23">[23]</xref> These features may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>A gray-green membrane deep into the retina, often&#x000a0;associated with an overlying neurosensory retinal detachment.</p>
          </list-item>
          <list-item>
            <p>Presence of blood, lipid, or subretinal fluid.</p>
          </list-item>
          <list-item>
            <p>RPE detachment appears clinically as dome-shaped, sharply demarcated elevations of the RPE,&#x000a0;which may also be serous, fibrovascular, drusenoid, or hemorrhagic.<xref ref-type="bibr" rid="article-133116.r24">[24]</xref>&#x000a0;A notch in serous PED may indicate the location of occult&#x000a0;CNV membranes.<xref ref-type="bibr" rid="article-133116.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Massive subretinal hemorrhage with central vision loss or, less commonly, breakthrough vitreous hemorrhage with peripheral vision loss (see <bold>Image</bold>.&#x000a0;Intraocular Hemorrhage&#x000a0;on Funduscopy).</p>
          </list-item>
          <list-item>
            <p>RPE tear or rip.<xref ref-type="bibr" rid="article-133116.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Disciform scars may be present, appearing as white or yellow subretinal membranes with or without RPE hyperplasia and pigmentation.</p>
          </list-item>
        </list>
        <p>The use of blood thinners and hematological disorders should be ruled out in patients with massive subretinal hemorrhage (the size of at least 4 disc areas).</p>
      </sec>
      <sec id="article-133116.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Accurate diagnosis of wet AMD relies on various ocular imaging techniques that assess retinal and choroidal changes. These modalities provide critical information for detecting and characterizing disease features and guiding treatment decisions. The ocular investigations recommended for&#x000a0;evaluating&#x000a0;wet AMD include the following:</p>
        <p>
<bold>Optical Coherence Tomography&#x000a0;</bold>
</p>
        <p>OCT is a noninvasive imaging modality that&#x000a0;can capture detailed images of the retina and surrounding structures.<xref ref-type="bibr" rid="article-133116.r27">[27]</xref>&#x000a0;OCT uses low-coherence light beams directed towards the target tissue.&#x000a0;The reflected light is combined with a reference beam and measured to create an interference pattern. This modality is used to reconstruct an axial A-scan. Multiple A-scans may be used to reconstruct a cross-sectional B-scan. Raster scans and three-dimensional images&#x000a0;may be produced from there. Features of wet AMD on macula OCT include the following:<xref ref-type="bibr" rid="article-133116.r28">[28]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Subretinal and intraretinal fluid</p>
          </list-item>
          <list-item>
            <p>Serous retinal PED, which is&#x000a0;observed as a homogenously hyporeflective space between the dome-shaped RPE and the Bruch membrane</p>
          </list-item>
          <list-item>
            <p>Fibrovascular PED (FVPED), which shows layers of moderate hyperreflectivity between the RPE and the Bruch membrane separated by hyporeflective clefts (see <bold>Image</bold>.&#x000a0;Fibrovascular&#x000a0;Retinal&#x000a0;Pigment&#x000a0;Epithelial&#x000a0;Detachment)</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic PED, which appears as a large, dome-shaped, hyperreflective lesion between the RPE and the Bruch membrane with attenuation of deeper structures</p>
          </list-item>
          <list-item>
            <p>RPE tears manifesting as areas of discontinuity in a large PED. The RPE edge may be observed&#x000a0;curled under the PED&#x000a0;<xref ref-type="bibr" rid="article-133116.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Disciform scarring with subretinal hyperreflective material and loss of the ellipsoid zone&#x000a0;<xref ref-type="bibr" rid="article-133116.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Optical Coherence Tomography&#x000a0;Angiography&#x000a0;</bold>
</p>
        <p>OCT angiography (OCTA) is a newer technology that creates images of the retinal circulation by obtaining sequential B-scans from a single area, and decorrelation signals are generated&#x000a0;to show only areas with movement, such as flow-through vessels.<xref ref-type="bibr" rid="article-133116.r31">[31]</xref>&#x000a0;OCTA may facilitate the earlier diagnosis of CNV, potentially identifying lesions before they are visible on&#x000a0;conventional OCT or fluorescein angiography.<xref ref-type="bibr" rid="article-133116.r32">[32]</xref></p>
        <p>
<bold>Fundus Fluorescein Angiography</bold>
</p>
        <p>Fundus fluorescein angiography (FFA) should be considered early in diagnosing wet AMD to&#x000a0;minimize diagnostic errors.<xref ref-type="bibr" rid="article-133116.r33">[33]</xref> OCT, the most frequent imaging modality used to make retreatment decisions in wet AMD,&#x000a0;is 85% sensitive yet only 48% specific for diagnosing active wet AMD.<xref ref-type="bibr" rid="article-133116.r34">[34]</xref> Thus, treatment decisions made solely on OCT findings may result in overtreatment.<xref ref-type="bibr" rid="article-133116.r35">[35]</xref><xref ref-type="bibr" rid="article-133116.r36">[36]</xref></p>
        <p>FFA has traditionally been used to classify CNVs as either classic or occult. This classification is particularly useful for treatment decisions, as photodynamic therapy (PDT) with verteporfin is often more effective for classic CNV, which comprises at least 50% of the lesion area, compared to occult CNV or minimally classic CNV, which occupies less than 50% of the lesion area.&#x000a0;<xref ref-type="bibr" rid="article-133116.r37">[37]</xref>&#x000a0;Classic CNV is marked by well-defined hyperfluorescence in early imaging phases, with leakage observed in the mid and late phases. Occult CNV is identified by FVPED showing stippled hyperfluorescent dots with or without leakage or by late leakage of an undetermined source, often appearing as speckled hyperfluorescence with subretinal dye pooling.</p>
        <p>Common FFA patterns in wet AMD may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>RAP (type 3 MNV), which is characterized by anastomosis between retinal and choroidal vessels and shows early hyperfluorescence, intraretinal hemorrhage, and vessels diving at right angles from the retina to the area of CNV (see <bold>Image</bold>.&#x000a0;Retinal Angiomatous Proliferation)</p>
          </list-item>
          <list-item>
            <p>Serous PED, which&#x000a0;may present with early, bright hyperfluorescence that is uniform in appearance and demonstrates little to no leakage</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic PED, which is characterized by the blocking of underlying choroidal fluorescence</p>
          </list-item>
          <list-item>
            <p>Drusenoid PED, with only faint fluorescence and lack of late staining or leakage</p>
          </list-item>
          <list-item>
            <p>Speckled hyperfluorescence&#x000a0;<xref ref-type="bibr" rid="article-133116.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Loculated fluid with fluorescein dye pooling anterior to the area of CNV</p>
          </list-item>
          <list-item>
            <p>RPE tears, which manifest as early hyperfluorescence with late staining of the choroid and sclera without leakage <xref ref-type="bibr" rid="article-133116.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Disciform scars, which may show staining or blocking if RPE hyperplasia is present</p>
          </list-item>
        </list>
        <p>
<bold>Indocyanine Green Angiography</bold>
</p>
        <p>ICGA is a dye that is helpful in imaging choroidal circulation, as it is highly protein-bound and less likely to leak from choroidal vessel fenestrations (see <bold>Image</bold>.&#x000a0;Polypoidal Choroidal Vasculopathy).<xref ref-type="bibr" rid="article-133116.r40">[40]</xref> ICGA is particularly effective in delineating occult CNV, which may manifest as:</p>
        <list list-type="bullet">
          <list-item>
            <p>A hot spot or area of early to mid-phase hyperfluorescence</p>
          </list-item>
          <list-item>
            <p>A plaque or area of late hyperfluorescence</p>
          </list-item>
          <list-item>
            <p>An area of poorly defined fluorescence <xref ref-type="bibr" rid="article-133116.r41">[41]</xref></p>
          </list-item>
        </list>
        <p>ICGA may be used to identify feeder vessels in CNV that may be treated with laser photocoagulation. This modality also better compares CNV subtypes, allowing for earlier diagnosis and determination of patient prognosis.<xref ref-type="bibr" rid="article-133116.r42">[42]</xref>&#x000a0;ICGA is very helpful in identifying idiopathic PCV, a close differential diagnosis of wet AMD. ICGA features of PCV include early focal subretinal hypercyanescence (polyps) within 6 min, pulsatile polyps, hypocyanescent halo around the polyp, and a branching vascular network.<xref ref-type="bibr" rid="article-133116.r43">[43]</xref> ICGA features of RAP include hot spots in the mid or late phase and retinochoroidal or retinal-retinal anastomoses, such as hairpin-like loops connecting a retinal arteriole and venule.<xref ref-type="bibr" rid="article-133116.r44">[44]</xref></p>
      </sec>
      <sec id="article-133116.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Intravitreal Anti-VEGF Therapy</bold>
</p>
        <p>The mainstay of therapy for wet AMD is intravitreal anti-VEGF treatment.&#x000a0;Currently used&#x000a0;agents prevent visual loss and may also improve vision in some cases.<xref ref-type="bibr" rid="article-133116.r45">[45]</xref></p>
        <p><bold>Pegaptanib sodium:&#x000a0;</bold>Pegaptanib sodium is the first&#x000a0;intravitreal anti-VEGF agent approved by the&#x000a0;Food and Drug Administration (FDA) for wet AMD treatment. This agent is a specific VEGF-165 antagonist, and it gained approval on&#x000a0;December 17, 2004.<xref ref-type="bibr" rid="article-133116.r46">[46]</xref>&#x000a0;However, pegaptanib sodium has largely been replaced by bevacizumab,&#x000a0;ranibizumab,&#x000a0;and aflibercept&#x000a0;due to improved results in various trials.<xref ref-type="bibr" rid="article-133116.r47">[47]</xref><xref ref-type="bibr" rid="article-133116.r48">[48]</xref>&#x000a0;The VISION study compared intravitreal pegaptanib with sham intravitreal injections in wet AMD and determined its efficacy in preventing vision loss.<xref ref-type="bibr" rid="article-133116.r49">[49]</xref></p>
        <p><bold>Ranibizumab:&#x000a0;</bold>Ranibizumab&#x000a0;is a recombinant humanized antibody fragment that binds all isoforms of VEGF-A. The FDA approved ranibizumab for wet AMD on June 30, 2006. The MARINA and ANCHOR&#x000a0;studies evaluated ranibizumab in minimally classic (occult) and classic CNV, respectively.<xref ref-type="bibr" rid="article-133116.r50">[50]</xref>&#x000a0;The ANCHOR trial showed superior efficacy of ranibizumab compared to PDT in classic CNV.<xref ref-type="bibr" rid="article-133116.r51">[51]</xref></p>
        <p><bold>Bevacizumab:&#x000a0;</bold>Bevacizumab is approved by the FDA for metastatic colorectal carcinoma but is used off-label for AMD treatment.<xref ref-type="bibr" rid="article-133116.r52">[52]</xref> Bevacizumab is&#x000a0;noninferior&#x000a0;to ranibizumab for this purpose, as evidenced&#x000a0;by multiple studies, including CATT, IVAN,&#x000a0;GEFAL,&#x000a0;LUCAS,&#x000a0;BRAMD, and MANTA.<xref ref-type="bibr" rid="article-133116.r53">[53]</xref><xref ref-type="bibr" rid="article-133116.r54">[54]</xref><xref ref-type="bibr" rid="article-133116.r55">[55]</xref><xref ref-type="bibr" rid="article-133116.r56">[56]</xref><xref ref-type="bibr" rid="article-133116.r57">[57]</xref><xref ref-type="bibr" rid="article-133116.r58">[58]</xref>&#x000a0;However, some studies have suggested a higher risk of serious systemic events with bevacizumab compared to ranibizumab, which may&#x000a0;need further investigation.<xref ref-type="bibr" rid="article-133116.r59">[59]</xref>&#x000a0;</p>
        <p><bold>Aflibercept:&#x000a0;</bold>Aflibercept&#x000a0;acts as a VEGF receptor decoy, effectively trapping all VEGF isoforms. This drug works against VEGF-A, VEGF-B, and the placental growth factor. Aflibercept is given every 2 months after the initial 3 monthly loading doses, and this dosing is as effective as monthly ranibizumab dosing.<xref ref-type="bibr" rid="article-133116.r60">[60]</xref>&#x000a0;The FDA approved&#x000a0;aflibercept&#x000a0;for wet AMD on November 18, 2011. VIEW 1 and VIEW 2 evaluated the role of fixed-dose aflibercept (initial 3 monthly injections or loading dose followed by intravitreal injection every 2 months) in wet AMD.<xref ref-type="bibr" rid="article-133116.r61">[61]</xref></p>
        <p>The FDA approved a high-dose aflibercept (8 mg/0.07 mL) formulation in August 2023 after it was shown to have efficacy and safety with extended dosing intervals without new safety signals (see <bold>Image.</bold> Intravitreal&#x000a0;Aflibercept&#x000a0;Injection Result).<xref ref-type="bibr" rid="article-133116.r62">[62]</xref>&#x000a0;The CLEAR-IT 2 study evaluated the as-needed protocol, with the initial 3 monthly injections followed by intravitreal injections as needed, using monthly evaluations with macula OCT.<xref ref-type="bibr" rid="article-133116.r63">[63]</xref></p>
        <p><bold>Ranibizumab-nuna:&#x000a0;</bold>Ranibizumab-nuna<bold>&#x000a0;</bold>is also also called SB11. This drug is the first ranibizumab biosimilar agent&#x000a0;to be approved by the FDA (approved on September 7, 2021) for patients with wet AMD.<xref ref-type="bibr" rid="article-133116.r64">[64]</xref>&#x000a0;Ranibizumab-eqrn<bold>&#x000a0;</bold>is another ranibizumab biosimilar approved by the FDA for use in patients with wet AMD (approved on August 2, 2022).<xref ref-type="bibr" rid="article-133116.r65">[65]</xref></p>
        <p><bold>Brolucizumab:&#x000a0;</bold>Brolucizumab&#x000a0;(ESBA 1008 or RTH 258)&#x000a0;is a low-molecular-weight VEGF antagonist that allows for a higher molar concentration of medication with each injection. The FDA approved&#x000a0;this drug on October 8, 2019 for use in wet AMD.&#x000a0;The drug was found to be noninferior to aflibercept every 12 weeks.<xref ref-type="bibr" rid="article-133116.r66">[66]</xref>&#x000a0;Despite early success with brolucizumab, concerns exist regarding reports of severe intraocular inflammation and vasculitis following administration.<xref ref-type="bibr" rid="article-133116.r67">[67]</xref>&#x000a0;HAWK and HARRIER trials evaluated brolucizumab's safety and efficacy in wet AMD.<xref ref-type="bibr" rid="article-133116.r68">[68]</xref></p>
        <p><bold>Aflibercept-jbvf</bold>
<bold>and</bold>
<bold>aflibercept-yszy:&#x000a0;</bold>Aflibercept-jbvf&#x000a0;and&#x000a0;aflibercept-yszy<bold>&#x000a0;</bold>are aflibercept biosimilars approved by the FDA in May 2024.&#x000a0;These agents are the first interchangeable biosimilars to aflibercept 2 mg.<xref ref-type="bibr" rid="article-133116.r69">[69]</xref></p>
        <p><bold>Faricimab-svoa:&#x000a0;</bold>Faricimab-svoa<bold>&#x000a0;</bold>is an antibody with an affinity for VEGF and angiopoietin-2, an additional factor that may drive inflammation and contribute to CNV development. Early reports&#x000a0;regarding faricimab are promising, with extended dosing intervals of 16 weeks shown to be noninferior to ranibizumab every 4 weeks.<xref ref-type="bibr" rid="article-133116.r70">[70]</xref>&#x000a0;The FDA approved faricimab for use in wet AMD on January 28, 2022. TENAYA and LUCERNE demonstrated noninferiority of faricimab compared to aflibercept in wet AMD.<xref ref-type="bibr" rid="article-133116.r71">[71]</xref> AVENUE and STAIRWAY trials compared faricimab with ranibizumab in wet AMD.<xref ref-type="bibr" rid="article-133116.r72">[72]</xref><xref ref-type="bibr" rid="article-133116.r73">[73]</xref></p>
        <p><bold>Treatment regimens: </bold>Anti-VEGF agents are administered according to various regimens:</p>
        <list list-type="bullet">
          <list-item>
            <p>Most anti-VEGF drugs are approved for&#x000a0;fixed dosage with the following possible schedules:
<list list-type="bullet"><list-item><p>Monthly or every 28 days (ranibizumab 0.5 mg)</p></list-item><list-item><p>Bimonthly after the initial 3 monthly (every 28 days) injections (aflibercept 2 mg)</p></list-item><list-item><p>Every&#x000a0;8 to 12 weeks (brolucizumab 6 mg) after the initial 3 monthly (every 25-31 days) doses</p></list-item><list-item><p>Up to every 16 weeks (faricimab 6 mg) after a loading dose of 4 monthly (every 28&#x000b1;7 days) injections</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>A&#x000a0;<italic toggle="yes">pro re nata</italic>&#x000a0;(PRN, or as needed) schedule where a patient receives injections only when the disease appears active, such as in subretinal&#x000a0;or intraretinal fluid on OCT, retinal hemorrhage, or leakage on fluorescein angiography.<xref ref-type="bibr" rid="article-133116.r74">[74]</xref></p>
          </list-item>
          <list-item>
            <p>A&#x000a0;treat-and-extend (TAE)&#x000a0;protocol, where injection frequency is slowly extended as long as disease activity remains controlled.<xref ref-type="bibr" rid="article-133116.r75">[75]</xref><xref ref-type="bibr" rid="article-133116.r76">[76]</xref></p>
          </list-item>
          <list-item>
            <p>A treat-extend-stop&#x000a0;protocol, where&#x000a0;the patient receives an anti-VEGF agent every month for at least 3 months until the OCT confirms dry macula. If the fovea remains dry, as per the TAE protocol, the interval between injections can increase by 1 to 2 weeks until a 12-week interval is reached. The injections are stopped in patients with at least 7 injections and dry macula at the third 12-week visit. Monthly evaluations are performed to monitor for CNV recurrence in approximately 30% of patients.<xref ref-type="bibr" rid="article-133116.r77">[77]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A treat-extend-pause-and-monitor protocol initially follows a TAE regimen.<xref ref-type="bibr" rid="article-133116.r78">[78]</xref>&#x000a0;Injections were paused in stable patients who had reached 12-weekly injections and started a PRN protocol. The patient was contacted 6 weeks after the last injection (18 weeks from the previous visit). If stable, no injection was given, and the patient was scheduled for a follow-up evaluation 12 weeks later.</p>
          </list-item>
        </list>
        <p>Although monthly injections are more effective compared to PRN regimens, evidence comparing PRN to TAE regimens remains inconclusive. Endophthalmitis is more likely with monthly injections, and patients receive more injections with monthly and TAE dosing compared to PRN. However, PRN regimens require more frequent clinic visits compared to TAE dosing.<xref ref-type="bibr" rid="article-133116.r79">[79]</xref></p>
        <p>Long-term data suggest that PRN dosing may result in slightly worse visual outcomes compared to monthly injections after a year. This difference may be clinically insignificant after a year&#x000a0;but may become&#x000a0;crucial after several years of treatment. Ultimately, the clinician and patient should work together to choose the best treatment option.</p>
        <p>Intravitreal anti-VEGF agents come with several risks. Common adverse events include subconjunctival hemorrhage and discomfort during or after the procedure, often due to the iodine-based antiseptic used to clean the ocular surface. Floaters may be caused by bubbles in the syringe or the medication itself. Serious adverse events rarely occur and can include vitreous hemorrhage or endophthalmitis.<xref ref-type="bibr" rid="article-133116.r80">[80]</xref></p>
        <p>Several studies have also explored potential systemic adverse events related to intravitreal anti-VEGF administration, including the risk of myocardial infarction, stroke, nonocular hemorrhage,&#x000a0;and thromboembolic events. Current evidence does not suggest an increase in systemic morbidity or mortality from the intravitreal administration of anti-VEGF agents. <xref ref-type="bibr" rid="article-133116.r81">[81]</xref>&#x000a0;However, this theoretical risk is still important to discuss with patients, especially those deemed to be at higher risk.&#x000a0;</p>
        <p>
<bold>Emerging Therapies</bold>
</p>
        <p>Several emerging therapies for wet AMD are currently under investigation. These treatments aim to improve existing options by exploring new mechanisms, delivery systems, and formulations to enhance efficacy and reduce treatment burden.</p>
        <p><bold>Abicipar pegol:&#x000a0;</bold>Abicipar pegol<bold>&#x000a0;</bold>is a nonmonoclonal antibody developed with designed ankyrin repeat protein&#x000a0;technology, with VEGF-binding affinity similar to aflibercept.<xref ref-type="bibr" rid="article-133116.r82">[82]</xref>&#x000a0;Similar to brolucizumab, its use may be limited due to higher reported rates of intraocular inflammation.<xref ref-type="bibr" rid="article-133116.r83">[83]</xref> Abicipar pegol was not approved by the FDA, citing an unfavorable risk-benefit ratio. Studies evaluating the role of abicipar pegol in wet AMD include CEDAR,&#x000a0;SEQUOIA,&#x000a0;CYPRESS, BAMBOO,&#x000a0;MAPLE, and REACH.<xref ref-type="bibr" rid="article-133116.r84">[84]</xref><xref ref-type="bibr" rid="article-133116.r85">[85]</xref></p>
        <p><bold>Conbercept:&#x000a0;</bold>Conbercept is a VEGF decoy protein similar to aflibercept that appears to have increased binding capacity to VEGF with an extended intraocular half-life, and FDA studies are underway.<xref ref-type="bibr" rid="article-133116.r86">[86]</xref><bold>&#x000a0;</bold>In addition, several sustained-release delivery devices are being developed to help decrease the burden of frequent intravitreal injections and reduce the potential for undertreatment.<xref ref-type="bibr" rid="article-133116.r87">[87]</xref>&#x000a0;</p>
        <p><bold>Ranibizumab port delivery system:&#x000a0;</bold>The ranibizumab port delivery system (PDS) was approved by the FDA on October 22, 2021 and<bold>&#x000a0;</bold>requires refill exchanges every 24 weeks.&#x000a0;This agent was shown to be noninferior to monthly ranibizumab.&#x000a0;However, the PDS&#x000a0;had a higher risk of adverse events compared to&#x000a0;ranibizumab monthly injections,&#x000a0;with higher rates of endophthalmitis, retinal detachments, vitreous hemorrhages, conjunctival erosions, and conjunctival retractions.<xref ref-type="bibr" rid="article-133116.r88">[88]</xref>&#x000a0;A voluntary recall for the implant was initiated in October 2022 due to concerns about septum dislodgement with repeated refill exchanges and failure of internal safety standards.<xref ref-type="bibr" rid="article-133116.r89">[89]</xref></p>
        <p>Other agents being evaluated for wet AMD include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>OPT-302, which&#x000a0;targets VEGF-C and VEGF-D</p>
          </list-item>
          <list-item>
            <p>KSI-301, which targets&#x000a0;VEGF-A</p>
          </list-item>
          <list-item>
            <p>Agents that counter platelet-derived growth factor (PDGF), including rinucumab, pegpleranib, X-82, DE-120, and CLS-AX</p>
          </list-item>
          <list-item>
            <p>Gene therapy, which&#x000a0;utilizes various vectors, including adeno-associated virus (AAV), to produce anti-VEGF agents such as VEGF receptor, ranibizumab, aflibercept, endostatin, and angiostatin</p>
          </list-item>
          <list-item>
            <p>Anti-tissue factor agents</p>
          </list-item>
          <list-item>
            <p>Sustained release devices,&#x000a0;including devices for delivering drugs such as ranibizumab and sunitinib (the latter&#x000a0;targets VEGF-A and PDGF)</p>
          </list-item>
        </list>
        <p>Topical medications being evaluated for wet AMD treatment include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Agents targeting VEGF-A and PDGF, such as&#x000a0;pazopanib, regorafenib, and PAN-90806</p>
          </list-item>
          <list-item>
            <p>Squalamine&#x000a0;targets VEGF, PDGF, and basic fibroblast growth factor</p>
          </list-item>
          <list-item>
            <p>LHA510 targets tyrosine kinase</p>
          </list-item>
        </list>
        <p>Oral medications evaluated for managing wet AMD include X-82, a tyrosine kinase inhibitor&#x000a0;blocking&#x000a0;VEGF and PDGF receptors, and&#x000a0;AKST4290, which targets CCR3, the receptor for eotaxin.<xref ref-type="bibr" rid="article-133116.r90">[90]</xref></p>
        <p>
<bold>Other Treatments</bold>
</p>
        <p>Before the&#x000a0;widespread use of anti-VEGF therapy, several other treatment modalities were employed for wet AMD. These modalities are&#x000a0;now less important due to the effectiveness and ongoing advancements of anti-VEGF treatments.</p>
        <p>Laser photocoagulation&#x000a0;is beneficial for foveal-sparing CNV lesions, although failure to adequately cover the entire lesion can lead to treatment failure and vision loss.<xref ref-type="bibr" rid="article-133116.r91">[91]</xref>&#x000a0;Laser photocoagulation destroys the overlying retinal tissue. Thus, this treatment should not be used for fovea-involving lesions, which are more likely to be visually devastating for patients.</p>
        <p>PDT is another treatment for CNV where the photosensitizing drug verteporfin is injected intravenously, and a low-intensity laser light treats the CNV tissue through a photochemical reaction that damages vascular endothelial cells, causing thrombosis.<xref ref-type="bibr" rid="article-133116.r92">[92]</xref>&#x000a0;Despite the lower intensity laser used in PDT, many patients still lose some vision after treatment. Anti-VEGF therapy has largely supplanted both laser photocoagulation and PDT in treating wet AMD.</p>
        <p>Submacular surgery&#x000a0;for patients with wet AMD has shown no benefit in patients with subfoveal CNV. This procedure also comes with the risk of cataract progression and retinal detachment.<xref ref-type="bibr" rid="article-133116.r93">[93]</xref>&#x000a0;Other surgical approaches for patients with CNV and vision loss include macular translocation surgery and mechanical displacement of subretinal hemorrhage with gas. Evidence is insufficient to recommend macular translocation unless the patient has severe, bilateral disease&#x000a0;unresponsive to anti-VEGF therapy.<xref ref-type="bibr" rid="article-133116.r94">[94]</xref></p>
        <p>Pneumatic displacement of submacular hemorrhage, using intravitreal air or gas injection with face-down positioning, may improve a patient's visual acuity.<xref ref-type="bibr" rid="article-133116.r95">[95]</xref>&#x000a0;Even in these patients, anti-VEGF therapy may be sufficient without surgical intervention.<xref ref-type="bibr" rid="article-133116.r96">[96]</xref>&#x000a0;Other approaches to managing massive submacular hemorrhage include intravitreal or subretinal tissue plasminogen activator, intravitreal gas, intravitreal anti-VEGF agents, pars plana vitrectomy,&#x000a0;subretinal air injection, and various combinations of therapies.<xref ref-type="bibr" rid="article-133116.r97">[97]</xref>&#x000a0;Subretinal injections of agents typically need pars plana vitrectomy.&#x000a0;</p>
        <p>Radiation therapy&#x000a0;has been considered for CNV in wet AMD, but studies have not found a clear benefit from this modality.&#x000a0;Radiation therapy combined with intravitreal ranibizumab is inferior to the as-needed use of ranibizumab monotherapy.<xref ref-type="bibr" rid="article-133116.r98">[98]</xref>&#x000a0;Evidence&#x000a0;currently does not&#x000a0;support the use of radiation therapy in wet AMD.</p>
        <p>An exciting new avenue of treatment for wet AMD is gene therapy.&#x000a0;RGX-314&#x000a0;is an AAV8 vector expressing an anti-VEGF-A fragment antigen-binding chain similar to ranibizumab. Subretinal delivery of the medication is generally safe and well-tolerated.<xref ref-type="bibr" rid="article-133116.r99">[99]</xref>&#x000a0;Phase 2 and 3 trials&#x000a0;are underway to test the safety and efficacy of subretinal and suprachoroidal delivery of RGX-314.</p>
      </sec>
      <sec id="article-133116.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for CNV due to wet AMD should include other potential causes of CNV.&#x000a0;Other conditions that must be considered include the following:</p>
        <table-wrap id="article-133116.table0" position="float" orientation="portrait">
          <table style="width: 400px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td style="width: 137.395px;" rowspan="1" colspan="1">Degenerative</td>
                <td style="width: 361.605px;" rowspan="1" colspan="1">
<p>Wet AMD</p>
<p>Pathological myopia</p>
<p>Angioid streak&#x000a0;<xref ref-type="bibr" rid="article-133116.r100">[100]</xref></p>
</td>
              </tr>
              <tr>
                <td style="width: 137.395px;" rowspan="1" colspan="1">Inflammatory</td>
                <td style="width: 361.605px;" rowspan="1" colspan="1">
<p>Presumed ocular histoplasmosis syndrome</p>
<p>Punctate inner choroidopathy</p>
<p>Serpiginous choroiditis</p>
<p>Serpiginous-like choroiditis</p>
<p>Multifocal choroiditis&#x000a0;</p>
<p>Sympathetic ophthalmia</p>
<p>Vogt-Koyanagi-Harada syndrome</p>
<p>Ocular tuberculosis&#x000a0;<xref ref-type="bibr" rid="article-133116.r101">[101]</xref><xref ref-type="bibr" rid="article-133116.r102">[102]</xref></p>
<p>Toxocariasis</p>
<p>Toxoplasmosis</p>
<p>Rubella</p>
</td>
              </tr>
              <tr>
                <td style="width: 137.395px;" rowspan="1" colspan="1">Trauma</td>
                <td style="width: 361.605px;" rowspan="1" colspan="1">
<p>Choroidal rupture</p>
<p>Laser burns</p>
<p>Iatrogenic (after vitreoretinal surgery)</p>
</td>
              </tr>
              <tr>
                <td style="width: 137.395px;" rowspan="1" colspan="1">Inherited retinal disorders</td>
                <td style="width: 361.605px;" rowspan="1" colspan="1">
<p>Best vitelliform macular dystrophy</p>
<p>Fundus flavimaculatus</p>
</td>
              </tr>
              <tr>
                <td style="width: 137.395px;" rowspan="1" colspan="1">Optic nerve disorders</td>
                <td style="width: 361.605px;" rowspan="1" colspan="1">Optic disc drusen</td>
              </tr>
              <tr>
                <td style="width: 137.395px;" rowspan="1" colspan="1">Tumors</td>
                <td style="width: 361.605px;" rowspan="1" colspan="1">
<p>Choroidal osteoma&#x000a0;<xref ref-type="bibr" rid="article-133116.r103">[103]</xref></p>
<p>Choroidal hemangioma</p>
<p>Choroidal nevus</p>
<p>Choroidal metastasis</p>
<p>Combined hamartoma of the retina and retinal pigment epithelium (CHRRPE)</p>
</td>
              </tr>
              <tr>
                <td style="width: 137.395px;" rowspan="1" colspan="1">Idiopathic</td>
                <td style="width: 361.605px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Breakthrough vitreous hemorrhage can also occur in wet AMD, and diagnosis may be challenging if the view is obscured during a dilated retinal examination. In such cases, evaluating the fellow eye or obtaining a detailed history can help establish the diagnosis. Other potential causes of vitreous hemorrhage include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Proliferative diabetic retinopathy</p>
          </list-item>
          <list-item>
            <p>Retinal tear or retinal detachment</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic posterior vitreous detachment</p>
          </list-item>
          <list-item>
            <p>Neovascularization from other causes, such as vein occlusions, radiation retinopathy, or sickle cell retinopathy</p>
          </list-item>
        </list>
        <p>PCV, a subtype of wet AMD more common in patients with Asian ancestry, is characterized by orangish-red, bulb-like subretinal polyps associated with adjacent subretinal hemorrhage or exudates. ICGA is crucial for diagnosing PCV, and recurrent disease is more common among PCV patients compared to those with wet AMD.&#x000a0;Patients with PCV may benefit more from PDT compared to&#x000a0;those with wet AMD.<xref ref-type="bibr" rid="article-133116.r104">[104]</xref>&#x000a0;</p>
        <p>Peripheral exudative hemorrhagic chorioretinopathy is a disease affecting older individuals characterized by peripheral subretinal or sub-RPE hemorrhage or exudates that may sometimes reach the posterior pole.<xref ref-type="bibr" rid="article-133116.r105">[105]</xref> Many such patients are hypertensive and on blood-thinning agents. This entity may be a variant of PCV, and around 60% of patients may show polyps on ICGA.<xref ref-type="bibr" rid="article-133116.r106">[106]</xref>&#x000a0;Treatment options include anti-VEGF agents, laser, PDT, pars plana vitrectomy, and cryotherapy.&#x000a0;Peripheral exudative hemorrhagic chorioretinopathy may simulate choroidal melanoma.<xref ref-type="bibr" rid="article-133116.r107">[107]</xref></p>
        <p>RAP should be kept in mind in patients with intraretinal hemorrhage near the fovea without evidence of diabetic retinopathy or macular branch retinal venous occlusion. This variant of wet AMD&#x000a0;typically starts at the deep capillary plexus and then grows outward.&#x000a0;The features include retinal-retinal anastomosis and retinal-choroidal anastomosis. The stages of RAP include stage 1 (intraretinal new vessels), stage 2 (subretinal new vessels), and stage 3 (choroidal or sub-RPE new vessels).&#x000a0;Stage 3 is characterized by retinal-choroidal anastomosis and vascularized PEDs.<xref ref-type="bibr" rid="article-133116.r108">[108]</xref>&#x000a0;Treatment is similar to types 1 and 2 MNV.</p>
      </sec>
      <sec id="article-133116.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>If left untreated for&#x000a0;2 to 3 years, around 50% to 60% of eyes with wet&#x000a0;AMD and subfoveal CNV lose 6 or more lines of vision, compared to 20% to 30% of eyes with any submacular CNV.<xref ref-type="bibr" rid="article-133116.r109">[109]</xref><xref ref-type="bibr" rid="article-133116.r110">[110]</xref><xref ref-type="bibr" rid="article-133116.r111">[111]</xref>&#x000a0;Classic CNV is associated with poorer visual outcomes compared to occult or minimally classic CNV,&#x000a0;and up to 50% of the patients without classic lesions on initial presentation may develop classic CNV within&#x000a0;1 year after diagnosis.<xref ref-type="bibr" rid="article-133116.r112">[112]</xref><xref ref-type="bibr" rid="article-133116.r113">[113]</xref></p>
        <p>Eyes with large subretinal hemorrhages that involve the fovea often have poor visual outcomes. However, some eyes have surprisingly good visual recovery, suggesting&#x000a0;that prompt treatment, such as intravitreal anti-VEGF medications or surgery, is still beneficial.<xref ref-type="bibr" rid="article-133116.r114">[114]</xref>&#x000a0;RPE tears involving the fovea also generally result in poor visual acuity and an elevated risk of vision loss from an RPE tear in the fellow eye.<xref ref-type="bibr" rid="article-133116.r115">[115]</xref></p>
      </sec>
      <sec id="article-133116.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Untreated wet AMD leads to irreversible vision loss in most patients. However, vision loss can still occur even with treatment. Patients with vision loss from AMD often report a diminished quality of life.<xref ref-type="bibr" rid="article-133116.r116">[116]</xref>&#x000a0;These individuals report significantly more emotional distress, poorer health, and less independence in daily activities compared to those with other chronic illnesses.<xref ref-type="bibr" rid="article-133116.r117">[117]</xref></p>
      </sec>
      <sec id="article-133116.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>All patients with macular drusen should be educated on the importance of regular Amsler grid use to check for metamorphopsias or scotomas that may indicate conversion from dry to wet AMD. Any change in near or distance vision may also indicate developing CNV,&#x000a0;prompting patients to contact their ophthalmologist immediately.</p>
        <p>Patients may also benefit from lifestyle modifications, including eating a well-balanced diet with plenty of micronutrients, wearing sunglasses to avoid excessive visible light exposure, and participating in regular exercise. Patients should regularly visit their primary care physician and control underlying systemic disorders. Selected patients should also be encouraged to use Age-Related Eye Disease Study (AREDS) or AREDS2 ingredients regularly. These vitamins have been shown to prevent progression to advanced AMD in patients with an intermediate or advanced disease in 1 eye.<xref ref-type="bibr" rid="article-133116.r118">[118]</xref><xref ref-type="bibr" rid="article-133116.r119">[119]</xref></p>
        <p>Patients already with severe vision loss may benefit from visual rehabilitation and referral to a low-vision clinic where they can obtain educational resources to help them function with their limited vision. Several low-vision tools may be offered, including handheld magnifiers, closed-circuit television viewers,&#x000a0;and accessibility applications on standard electronic devices,&#x000a0;such as smartphones and tablets. Patients should be informed about the availability of large-print periodicals, audiobooks, and other resources offered by their local library and the Library of Congress. These individuals may also benefit from a referral to social services to help preserve their independence as much as possible.</p>
      </sec>
      <sec id="article-133116.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with wet AMD are typically evaluated by an interprofessional healthcare&#x000a0;team, which may include&#x000a0;a retina specialist. Primary care providers, optometrists, and general ophthalmologists play a crucial role in recognizing the signs and symptoms of worsening wet AMD and referring patients to a retina specialist or other clinicians trained in treating wet AMD and administering intravitreal injections. Expeditious diagnosis and treatment&#x000a0;are crucial for preventing irreversible vision loss. Pharmacists can provide the team and the patient with information on the drugs used, including potential interactions and adverse events, and verify proper dosing. Interprofessional teamwork is vital for achieving the best patient outcomes in wet AMD.</p>
        <p>Although retina specialists are traditionally responsible for administering intravitreal anti-VEGF agents, there is a shortage of these specialists, particularly in rural areas. The growing aging population in developed countries has prompted more comprehensive ophthalmologists to learn how to evaluate and treat wet AMD. Despite this trend, comprehensive ophthalmologists should understand&#x000a0;that caring for patients with wet AMD requires&#x000a0;complex decision-making based on individual vitreoretinal pathology. Consultation or co-management with a retina specialist is recommended.</p>
        <p>Patients with advanced AMD should be considered for early referral for low-vision services. Vision impairment in patients with wet AMD can prevent them from performing activities of daily living, and several aids are available to allow patients to read and perform other tasks.<xref ref-type="bibr" rid="article-133116.r120">[120]</xref><xref ref-type="bibr" rid="article-133116.r121">[121]</xref></p>
      </sec>
      <sec id="article-133116.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=133116&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=133116">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/wet-age-related-macular-degeneration-amd/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=133116">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/133116/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=133116">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-133116.s16">
        <fig id="article-133116.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Intravitreal Aflibercept Injection Result. Optical coherence tomography image of an eye before (top) and 4 weeks after (bottom) intravitreal aflibercept injection. A significant reduction is observed in the subretinal fluid (hyporeflective area under the retina) after injection. Contributed by SD Hobbs, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Aflibercept" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-133116.s17">
        <fig id="article-133116.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Amsler Grid. This image shows the Amsler grid, as observed by a normal eye (left) and one with wet age-related macular degeneration (right), demonstrating distortion and a paracentral scotoma. All patients with macular drusen should be educated on the importance of regular use of the Amsler grid to detect new-onset distortion or scotomas that may indicate conversion from dry to wet ARMD. Contributed by SD Hobbs, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AG__copy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-133116.s18">
        <fig id="article-133116.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Age-Related Macular Degeneration on Funduscopy. This fundus photo of a left eye demonstrates drusen with a submacular hemorrhage, a complication of wet (exudative or neovascular) age-related macular degeneration. Contributed by SD Hobbs, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="submacular__heme__copy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-133116.s19">
        <fig id="article-133116.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Retinal Pigment Epithelial Detachment. This optical coherence tomography image shows neovascular age-related macular degeneration with subretinal fluid, retinal pigment epithelial detachment, and subretinal hyperreflective material. M Musa, OD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="WET__AMD" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-133116.s20">
        <fig id="article-133116.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Fibrovascular Retinal Pigment Epithelial Detachment. This optical coherence tomography image shows wet age-related macular degeneration with fibrovascular retinal pigment epithelial detachment and intraretinal fluid. M Musa, OD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Fibrovascular__PED__with__IRF__" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-133116.s21">
        <fig id="article-133116.image.f6" position="float" orientation="portrait">
          <caption>
            <p>Intraocular Hemorrhage&#x000a0;on Funduscopy. This image illustrates a hemorrhagic choroidal neovascular membrane observed on funduscopy. Contributed by U Shukla, MS, DNB, FVRS, MNAMS, PhD&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hemorrhagic__CNVM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-133116.s22">
        <fig id="article-133116.image.f7" position="float" orientation="portrait">
          <caption>
            <p>Peripapillary Choroidal Neovascular Membrane. This optical coherence tomography image shows a peripapillary choroidal neovascular membrane with subretinal hyperreflective material and fluid. SRM, subretinal fluid; SHRM, subretinal hyperreflective material. M Musa, OD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="SHRM__with__SRF" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-133116.s23">
        <fig id="article-133116.image.f8" position="float" orientation="portrait">
          <caption>
            <p>Retinal Angiomatous Proliferation. These images from funduscopy (left) and fundus fluorescein angiography (middle and right) show&#x000a0;retinal angiomatous proliferation features. Contributed by S Muraleedharan, MS; Aravind Eye Hospital</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="RAP" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-133116.s24">
        <fig id="article-133116.image.f9" position="float" orientation="portrait">
          <caption>
            <p>Polypoidal Choroidal Vasculopathy. These images show features of a left eye with polypoidal choroidal vasculopathy through fluorescein angiography (A) and indocyanine green angiography (B). Contributed by S Muraleedharan, MS; Aravind Eye Hospital</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PCV" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-133116.s25">
        <title>References</title>
        <ref id="article-133116.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>EEM</given-names>
              </name>
              <name>
                <surname>Valsecchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;tz</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>A review of interactions between peripheral and foveal vision.</article-title>
            <source>J Vis</source>
            <year>2020</year>
            <month>Nov</month>
            <day>02</day>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">33141171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>O'Colmain</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tomany</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>McCarty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Nemesure</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kempen</surname>
                <given-names>J</given-names>
              </name>
              <collab>Eye Diseases Prevalence Research Group</collab>
            </person-group>
            <article-title>Prevalence of age-related macular degeneration in the United States.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>564</fpage>
            <page-range>564-72</page-range>
            <pub-id pub-id-type="pmid">15078675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spraul</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Grossniklaus</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes.</article-title>
            <source>Surv Ophthalmol</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>44 Suppl 1</volume>
            <fpage>S10</fpage>
            <page-range>S10-32</page-range>
            <pub-id pub-id-type="pmid">10548114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>5397</fpage>
            <page-range>5397-405</page-range>
            <pub-id pub-id-type="pmid">26451092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chew</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Clemons</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Agr&#x000f3;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sperduto</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Sangiovanni</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>FL</given-names>
              </name>
              <collab>Age-Related Eye Disease Study Research Group</collab>
            </person-group>
            <article-title>Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>272</fpage>
            <page-range>272-7</page-range>
            <pub-id pub-id-type="pmid">24385141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomany</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Van Leeuwen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vingerling</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>De Jong</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for incident age-related macular degeneration: pooled findings from 3 continents.</article-title>
            <source>Ophthalmology</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>111</volume>
            <issue>7</issue>
            <fpage>1280</fpage>
            <page-range>1280-7</page-range>
            <pub-id pub-id-type="pmid">15234127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsi</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Marketou</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Vrachatis</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Manolis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nihoyannopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tousoulis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vardas</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Kallikazaros</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Essential hypertension in the pathogenesis of age-related macular degeneration: a review of the current evidence.</article-title>
            <source>J Hypertens</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>2382</fpage>
            <page-range>2382-8</page-range>
            <pub-id pub-id-type="pmid">26536087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Age-related macular degeneration: genome-wide association studies to translation.</article-title>
            <source>Genet Med</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <page-range>283-9</page-range>
            <pub-id pub-id-type="pmid">26020418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kauppinen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paterno</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Blasiak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Salminen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaarniranta</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Inflammation and its role in age-related macular degeneration.</article-title>
            <source>Cell Mol Life Sci</source>
            <year>2016</year>
            <month>May</month>
            <volume>73</volume>
            <issue>9</issue>
            <fpage>1765</fpage>
            <page-range>1765-86</page-range>
            <pub-id pub-id-type="pmid">26852158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schultz</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Humpert</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Luzier</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Persun</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Runckel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cassera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vittal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Weleber</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Acott</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family.</article-title>
            <source>Hum Mol Genet</source>
            <year>2003</year>
            <month>Dec</month>
            <day>15</day>
            <volume>12</volume>
            <issue>24</issue>
            <fpage>3315</fpage>
            <page-range>3315-23</page-range>
            <pub-id pub-id-type="pmid">14570714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.</article-title>
            <source>Lancet Glob Health</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>e106</fpage>
            <page-range>e106-16</page-range>
            <pub-id pub-id-type="pmid">25104651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonas</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>CMG</given-names>
              </name>
              <name>
                <surname>Panda-Jonas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Updates on the Epidemiology of Age-Related Macular Degeneration.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2017</year>
            <season>Nov-Dec</season>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>493</fpage>
            <page-range>493-497</page-range>
            <pub-id pub-id-type="pmid">28906084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gehrs</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Hageman</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.</article-title>
            <source>Ann Med</source>
            <year>2006</year>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>450</fpage>
            <page-range>450-71</page-range>
            <pub-id pub-id-type="pmid">17101537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferris</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hyman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Age-related macular degeneration and blindness due to neovascular maculopathy.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>11</issue>
            <fpage>1640</fpage>
            <page-range>1640-2</page-range>
            <pub-id pub-id-type="pmid">6208888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Enger</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture.</article-title>
            <source>Ophthalmology</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>100</volume>
            <issue>10</issue>
            <fpage>1519</fpage>
            <page-range>1519-35</page-range>
            <pub-id pub-id-type="pmid">7692366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ambati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ambati</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ianchulev</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adamis</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2003</year>
            <season>May-Jun</season>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-93</page-range>
            <pub-id pub-id-type="pmid">12745003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaimov</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Panova</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Shaimov</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Shaimov&#x00430;</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Shai Mova</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Fomin</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Shaimov</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Panova</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Shaimov</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Shaimova</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Shaimova</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Fomin</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>[Optical coherence tomography angiography in the diagnosis of neovascular age-related macular degeneration].</article-title>
            <source>Vestn Oftalmol</source>
            <year>2015</year>
            <season>Sep-Oct</season>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>4</fpage>
            <page-range>4-13</page-range>
            <pub-id pub-id-type="pmid">26845866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gass</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1994</year>
            <month>Sep</month>
            <day>15</day>
            <volume>118</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-98</page-range>
            <pub-id pub-id-type="pmid">7521987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Barbazetto</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Koizumi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laud</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sorenson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Yannuzzi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation.</article-title>
            <source>Retina</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-11</page-range>
            <pub-id pub-id-type="pmid">18301024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yannuzzi</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Review of retinal angiomatous proliferation or type 3 neovascularization.</article-title>
            <source>Retina</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>375</fpage>
            <page-range>375-84</page-range>
            <pub-id pub-id-type="pmid">18327130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spaide</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Sarraf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Sadda</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Staurenghi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Waheed</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Chakravarthy</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Holz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Souied</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Querques</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gaudric</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blodi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Baumal</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Coscas</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Brucker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singerman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luthert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmitz-Valckenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Grossniklaus</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Guymer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yannuzzi</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Csaky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mon&#x000e9;s</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pauleikhoff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tadayoni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>May</month>
            <volume>127</volume>
            <issue>5</issue>
            <fpage>616</fpage>
            <page-range>616-636</page-range>
            <pub-id pub-id-type="pmid">31864668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fine</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Elman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Prestia</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Starr</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Earliest symptoms caused by neovascular membranes in the macula.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1986</year>
            <month>Apr</month>
            <volume>104</volume>
            <issue>4</issue>
            <fpage>513</fpage>
            <page-range>513-4</page-range>
            <pub-id pub-id-type="pmid">2420316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gragoudas</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of choroidal neovascular membranes.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1987</year>
            <month>Feb</month>
            <volume>105</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-13</page-range>
            <pub-id pub-id-type="pmid">2434067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zayit-Soudry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moroz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Loewenstein</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Retinal pigment epithelial detachment.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2007</year>
            <season>May-Jun</season>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-43</page-range>
            <pub-id pub-id-type="pmid">17472800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gass</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Serous retinal pigment epithelial detachment with a notch. A sign of occult choroidal neovascularization.</article-title>
            <source>Retina</source>
            <year>1984</year>
            <season>Fall-Winter</season>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>205</fpage>
            <page-range>205-20</page-range>
            <pub-id pub-id-type="pmid">6085179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A 56-year-old male with unilateral painless diminution of vision.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2016</year>
            <season>May-Aug</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <pub-id pub-id-type="pmid">27433043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drexler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>State-of-the-art retinal optical coherence tomography.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-88</page-range>
            <pub-id pub-id-type="pmid">18036865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spaide</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>147</volume>
            <issue>4</issue>
            <fpage>644</fpage>
            <page-range>644-52</page-range>
            <pub-id pub-id-type="pmid">19152869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Sarraf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Tears of the retinal pigment epithelium: an old problem in a new era.</article-title>
            <source>Retina</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>523</fpage>
            <page-range>523-34</page-range>
            <pub-id pub-id-type="pmid">17558312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Seiple</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Inner segment-outer segment junctional layer integrity and corresponding retinal sensitivity in dry and wet forms of age-related macular degeneration.</article-title>
            <source>Retina</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>364</fpage>
            <page-range>364-70</page-range>
            <pub-id pub-id-type="pmid">21221051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tokayer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Potsaid</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Subhash</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Hornegger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Split-spectrum amplitude-decorrelation angiography with optical coherence tomography.</article-title>
            <source>Opt Express</source>
            <year>2012</year>
            <month>Feb</month>
            <day>13</day>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>4710</fpage>
            <page-range>4710-25</page-range>
            <pub-id pub-id-type="pmid">22418228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nesper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fawzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Skondra</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Optical Coherence Tomographic Angiography Imaging in Age-Related Macular Degeneration.</article-title>
            <source>Ophthalmol Eye Dis</source>
            <year>2017</year>
            <volume>9</volume>
            <fpage>1179172116686075</fpage>
            <pub-id pub-id-type="pmid">28579843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ruia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Fluorescein Angiography</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35015403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mowatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elders</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lois</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amoaku</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Burr</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lotery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Azuara-Blanco</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>122</volume>
            <issue>2</issue>
            <fpage>399</fpage>
            <page-range>399-406</page-range>
            <pub-id pub-id-type="pmid">25444343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schachat</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Optical coherence tomography, fluorescein angiography, and the management of neovascular age-related macular degeneration.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>122</volume>
            <issue>2</issue>
            <fpage>222</fpage>
            <page-range>222-3</page-range>
            <pub-id pub-id-type="pmid">25618425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbazetto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Burdan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kapetanios</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lukas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reaves</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schachat</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Wenkstern</surname>
                <given-names>A</given-names>
              </name>
              <collab>Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group</collab>
              <collab>Verteporfin in Photodynamic Therapy Study Group</collab>
            </person-group>
            <article-title>Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>121</volume>
            <issue>9</issue>
            <fpage>1253</fpage>
            <page-range>1253-68</page-range>
            <pub-id pub-id-type="pmid">12963608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <article-title>Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>117</volume>
            <issue>10</issue>
            <fpage>1329</fpage>
            <page-range>1329-45</page-range>
            <pub-id pub-id-type="pmid">10532441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dyer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Brant</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Schachat</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Angiographic features and outcome of questionable recurrent choroidal neovascularization.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1995</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>4</issue>
            <fpage>497</fpage>
            <page-range>497-505</page-range>
            <pub-id pub-id-type="pmid">7573308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chuang</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>The pathogenesis of tears of the retinal pigment epithelium.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1988</year>
            <month>Mar</month>
            <day>15</day>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-90</page-range>
            <pub-id pub-id-type="pmid">2449819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r40">
          <label>40</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Muraleedharan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Indocyanine Green (ICG) Angiography</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35593804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regillo</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Annesley</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Indocyanine green angiography and occult choroidal neovascularization.</article-title>
            <source>Ophthalmology</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>280</fpage>
            <page-range>280-8</page-range>
            <pub-id pub-id-type="pmid">7509471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bottoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Massacesi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cigada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Musicco</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Staurenghi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>123</volume>
            <issue>12</issue>
            <fpage>1644</fpage>
            <page-range>1644-50</page-range>
            <pub-id pub-id-type="pmid">16344434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hashad</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Pilz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruamviboonsuk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tokaji</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weisberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.</article-title>
            <source>Retina</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>1453</fpage>
            <page-range>1453-64</page-range>
            <pub-id pub-id-type="pmid">22426346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Itagaki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Angiographic results of retinal-retinal anastomosis and retinal-choroidal anastomosis after treatments in eyes with retinal angiomatous proliferation.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2012</year>
            <volume>6</volume>
            <fpage>1385</fpage>
            <page-range>1385-91</page-range>
            <pub-id pub-id-type="pmid">22969283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaiser</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Arepalli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ehlers</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration.</article-title>
            <source>J Exp Pharmacol</source>
            <year>2021</year>
            <volume>13</volume>
            <fpage>905</fpage>
            <page-range>905-912</page-range>
            <pub-id pub-id-type="pmid">34616189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group</collab>
              <name>
                <surname>D'Amico</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Masonson</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adamis</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Guyer</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.</article-title>
            <source>Ophthalmology</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>113</volume>
            <issue>6</issue>
            <fpage>992</fpage>
            <page-range>992-1001.e6</page-range>
            <pub-id pub-id-type="pmid">16647134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>CATT Research Group</collab>
              <name>
                <surname>Martin</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Grunwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab and bevacizumab for neovascular age-related macular degeneration.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>May</month>
            <day>19</day>
            <volume>364</volume>
            <issue>20</issue>
            <fpage>1897</fpage>
            <page-range>1897-908</page-range>
            <pub-id pub-id-type="pmid">21526923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Korobelnik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Soo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Anderesi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Groetzbach</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sommerauer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sandbrink</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simader</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <collab>VIEW 1 and VIEW 2 Study Groups</collab>
            </person-group>
            <article-title>Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.</article-title>
            <source>Ophthalmology</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>119</volume>
            <issue>12</issue>
            <fpage>2537</fpage>
            <page-range>2537-48</page-range>
            <pub-id pub-id-type="pmid">23084240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gragoudas</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Adamis</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Feinsod</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guyer</surname>
                <given-names>DR</given-names>
              </name>
              <collab>VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group</collab>
            </person-group>
            <article-title>Pegaptanib for neovascular age-related macular degeneration.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Dec</month>
            <day>30</day>
            <volume>351</volume>
            <issue>27</issue>
            <fpage>2805</fpage>
            <page-range>2805-16</page-range>
            <pub-id pub-id-type="pmid">15625332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RY</given-names>
              </name>
              <collab>MARINA Study Group</collab>
            </person-group>
            <article-title>Ranibizumab for neovascular age-related macular degeneration.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Oct</month>
            <day>05</day>
            <volume>355</volume>
            <issue>14</issue>
            <fpage>1419</fpage>
            <page-range>1419-31</page-range>
            <pub-id pub-id-type="pmid">17021318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soubrane</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Sy</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>S</given-names>
              </name>
              <collab>ANCHOR Study Group</collab>
            </person-group>
            <article-title>Ranibizumab versus verteporfin for neovascular age-related macular degeneration.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Oct</month>
            <day>05</day>
            <volume>355</volume>
            <issue>14</issue>
            <fpage>1432</fpage>
            <page-range>1432-44</page-range>
            <pub-id pub-id-type="pmid">17021319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Intraocular use of bevacizumab in India: An issue resolved?</article-title>
            <source>Natl Med J India</source>
            <year>2017</year>
            <season>Nov-Dec</season>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>345</fpage>
            <page-range>345-347</page-range>
            <pub-id pub-id-type="pmid">30117450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group</collab>
              <name>
                <surname>Martin</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Grunwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Redford</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.</article-title>
            <source>Ophthalmology</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>119</volume>
            <issue>7</issue>
            <fpage>1388</fpage>
            <page-range>1388-98</page-range>
            <pub-id pub-id-type="pmid">22555112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>IVAN Study Investigators</collab>
              <name>
                <surname>Chakravarthy</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Downes</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lotery</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wordsworth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.</article-title>
            <source>Ophthalmology</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>119</volume>
            <issue>7</issue>
            <fpage>1399</fpage>
            <page-range>1399-411</page-range>
            <pub-id pub-id-type="pmid">22578446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kodjikian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Souied</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Mimoun</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mauget-Fa&#x000ff;sse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Behar-Cohen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Decullier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aulagner</surname>
                <given-names>G</given-names>
              </name>
              <collab>GEFAL Study Group</collab>
            </person-group>
            <article-title>Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>120</volume>
            <issue>11</issue>
            <fpage>2300</fpage>
            <page-range>2300-9</page-range>
            <pub-id pub-id-type="pmid">23916488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Sandvik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bragad&#x000f3;ttir</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>122</volume>
            <issue>1</issue>
            <fpage>146</fpage>
            <page-range>146-52</page-range>
            <pub-id pub-id-type="pmid">25227499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schauwvlieghe</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dijkman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hooymans</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Verbraak</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Hoyng</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Dijkgraaf</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vingerling</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Schlingemann</surname>
                <given-names>RO</given-names>
              </name>
            </person-group>
            <article-title>Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>e0153052</fpage>
            <pub-id pub-id-type="pmid">27203434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krebs</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schmetterer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boltz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Told</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>V&#x000e9;csei-Marlovits</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Egger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;nherr</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ansari-Shahrezaei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Binder</surname>
                <given-names>S</given-names>
              </name>
              <collab>MANTA Research Group</collab>
            </person-group>
            <article-title>A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>266</fpage>
            <page-range>266-71</page-range>
            <pub-id pub-id-type="pmid">23292928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>e101253</fpage>
            <pub-id pub-id-type="pmid">24983855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Korobelnik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Simader</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Slakter</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Soo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Anderesi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sowade</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zeitz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Norenberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sandbrink</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>193</fpage>
            <page-range>193-201</page-range>
            <pub-id pub-id-type="pmid">24084500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Mandava</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>1573</fpage>
            <page-range>1573-80</page-range>
            <pub-id pub-id-type="pmid">19694600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanzetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korobelnik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Leal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Eichenbaum</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Iida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xiaodong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Schulze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmelter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schmidt-Ott</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hirshberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <collab>PULSAR Investigators</collab>
            </person-group>
            <article-title>Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2024</year>
            <month>Mar</month>
            <day>23</day>
            <volume>403</volume>
            <issue>10432</issue>
            <fpage>1141</fpage>
            <page-range>1141-1152</page-range>
            <pub-id pub-id-type="pmid">38461841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ingerman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <collab>CLEAR-IT 2 Investigators</collab>
            </person-group>
            <article-title>The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.</article-title>
            <source>Ophthalmology</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>118</volume>
            <issue>6</issue>
            <fpage>1098</fpage>
            <page-range>1098-106</page-range>
            <pub-id pub-id-type="pmid">21640258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis<sup>&#x000ae;</sup> (Ranibizumab) Biosimilar.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>639</fpage>
            <page-range>639-652</page-range>
            <pub-id pub-id-type="pmid">35084693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwahashi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parachuri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Loewenstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuppermann</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Approved biosimilar ranibizumab-a global update.</article-title>
            <source>Eye (Lond)</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-202</page-range>
            <pub-id pub-id-type="pmid">36114290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dugel</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Warburton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weichselberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holz</surname>
                <given-names>FG</given-names>
              </name>
              <collab>HAWK and HARRIER Study Investigators</collab>
            </person-group>
            <article-title>HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-84</page-range>
            <pub-id pub-id-type="pmid">30986442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumal</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Spaide</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Vajzovic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lakhanpal</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Oellers</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Leveque</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Rutledge</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Chittum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bacci</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Enriquez</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Sund</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Subong</surname>
                <given-names>ENP</given-names>
              </name>
              <name>
                <surname>Albini</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>127</volume>
            <issue>10</issue>
            <fpage>1345</fpage>
            <page-range>1345-1359</page-range>
            <pub-id pub-id-type="pmid">32344075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dugel</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Weissgerber</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gedif</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Tadayoni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Holz</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.</article-title>
            <source>Ophthalmology</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-99</page-range>
            <pub-id pub-id-type="pmid">32574761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bradvica</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vajas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sagong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ernest</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Studnicka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Veith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wylegala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Orski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Astakhov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>T&#x000f3;th-Moln&#x000e1;r</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Csutak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Enyedi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sadda</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2023</year>
            <month>Jul</month>
            <day>01</day>
            <volume>141</volume>
            <issue>7</issue>
            <fpage>668</fpage>
            <page-range>668-676</page-range>
            <pub-id pub-id-type="pmid">37289448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicol&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferro Desideri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vagge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Traverso</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>193</fpage>
            <page-range>193-200</page-range>
            <pub-id pub-id-type="pmid">33471572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Khanani</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Quezada Ruiz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ferrone</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Brittain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Holz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>TYY</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Regillo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Swaminathan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>CMG</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <collab>TENAYA and LUCERNE Investigators</collab>
            </person-group>
            <article-title>Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.</article-title>
            <source>Lancet</source>
            <year>2022</year>
            <month>Feb</month>
            <day>19</day>
            <volume>399</volume>
            <issue>10326</issue>
            <fpage>729</fpage>
            <page-range>729-740</page-range>
            <pub-id pub-id-type="pmid">35085502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dugel</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chittum</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Del Valle Rubido</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sadikhov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Szczesny</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nogoceke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weikert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fauser</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>138</volume>
            <issue>9</issue>
            <fpage>955</fpage>
            <page-range>955-963</page-range>
            <pub-id pub-id-type="pmid">32729888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanani</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ferrone</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sahni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grzeschik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ehrlich</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Haskova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dugel</surname>
                <given-names>PU</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>138</volume>
            <issue>9</issue>
            <fpage>964</fpage>
            <page-range>964-972</page-range>
            <pub-id pub-id-type="pmid">32729897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lalwani</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Dubovy</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feuer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Esquiabro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>148</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-58.e1</page-range>
            <pub-id pub-id-type="pmid">19376495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Augsburger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarra</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Imesch</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>257</volume>
            <issue>9</issue>
            <fpage>1889</fpage>
            <page-range>1889-1895</page-range>
            <pub-id pub-id-type="pmid">31256237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kertes</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Galic</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Greve</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lahaie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sheidow</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>138</volume>
            <issue>3</issue>
            <fpage>244</fpage>
            <page-range>244-250</page-range>
            <pub-id pub-id-type="pmid">31917441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adrean</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Chaili</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pirouz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed&#x000a0;with a Treat-Extend-Stop Protocol.</article-title>
            <source>Ophthalmol Retina</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>225</fpage>
            <page-range>225-230</page-range>
            <pub-id pub-id-type="pmid">31047590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dinabandhu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Daoud</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Handa</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Montaner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sodhi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy.</article-title>
            <source>J Clin Invest</source>
            <year>2022</year>
            <month>Jan</month>
            <day>18</day>
            <volume>132</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">34874918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindsley</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Krzystolik</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>May</month>
            <day>05</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD012208</fpage>
            <pub-id pub-id-type="pmid">32374423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakri</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ehlers</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Schoenberger</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology.</article-title>
            <source>Ophthalmology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-63</page-range>
            <pub-id pub-id-type="pmid">30077616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moja</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lucenteforte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kwag</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Bertele</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Campomori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chakravarthy</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dickersin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kodjikian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lindsley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Loke</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Mugelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;hlbauer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>P&#x000fc;ntmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schmucker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Sep</month>
            <day>15</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>CD011230</fpage>
            <pub-id pub-id-type="pmid">25220133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuppermann</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Abicipar pegol: the non-monoclonal antibody anti-VEGF.</article-title>
            <source>Eye (Lond)</source>
            <year>2020</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>797</fpage>
            <page-range>797-801</page-range>
            <pub-id pub-id-type="pmid">31570812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunimoto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wykoff</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khurana</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Maturi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Agostini</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Souied</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Lotery</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ohji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Belfort</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hashad</surname>
                <given-names>Y</given-names>
              </name>
              <collab>CEDAR and SEQUOIA Study Groups</collab>
            </person-group>
            <article-title>Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>127</volume>
            <issue>10</issue>
            <fpage>1331</fpage>
            <page-range>1331-1344</page-range>
            <pub-id pub-id-type="pmid">32471729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khurana</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Kunimoto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wykoff</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maturi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Agostini</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Souied</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Lotery</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ohji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Belfort</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hashad</surname>
                <given-names>Y</given-names>
              </name>
              <collab>CEDAR and SEQUOIA Study Groups</collab>
            </person-group>
            <article-title>Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration.</article-title>
            <source>Ophthalmology</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>128</volume>
            <issue>7</issue>
            <fpage>1027</fpage>
            <page-range>1027-1038</page-range>
            <pub-id pub-id-type="pmid">33221326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunimoto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ohji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maturi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Sekiryu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>S</given-names>
              </name>
              <collab>BAMBOO and CYPRESS Study Groups</collab>
            </person-group>
            <article-title>Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States.</article-title>
            <source>Ophthalmic Surg Lasers Imaging Retina</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>e10</fpage>
            <page-range>e10-e22</page-range>
            <pub-id pub-id-type="pmid">30768224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferro Desideri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Traverso</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Nicol&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An update on conbercept to treat wet age-related macular degeneration.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2020</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>311</fpage>
            <page-range>311-320</page-range>
            <pub-id pub-id-type="pmid">32406878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2020</year>
            <volume>14</volume>
            <fpage>1349</fpage>
            <page-range>1349-1355</page-range>
            <pub-id pub-id-type="pmid">32546942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holekamp</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Campochiaro</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pieramici</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adamis</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Brittain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maass</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ranade</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barteselli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Regillo</surname>
                <given-names>C</given-names>
              </name>
              <collab>all Archway Investigators</collab>
            </person-group>
            <article-title>Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.</article-title>
            <source>Ophthalmology</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-307</page-range>
            <pub-id pub-id-type="pmid">34597713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanani</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Parachuri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuppermann</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists.</article-title>
            <source>Int J Retina Vitreous</source>
            <year>2023</year>
            <month>Jan</month>
            <day>30</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">36717931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arepalli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Pipeline therapies for neovascular age related macular degeneration.</article-title>
            <source>Int J Retina Vitreous</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">34598731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <article-title>The influence of treatment extent on the visual acuity of eyes treated with Krypton laser for juxtafoveal choroidal neovascularization. Macular Photocoagulation Study Group.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>113</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-4</page-range>
            <pub-id pub-id-type="pmid">7532395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Sickenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laqua</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barbazetto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gragoudas</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Zografos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Piguet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pournaras</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Birngruber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Manjuris</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fsadni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>117</volume>
            <issue>9</issue>
            <fpage>1177</fpage>
            <page-range>1177-87</page-range>
            <pub-id pub-id-type="pmid">10496389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giansanti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eandi</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2009</year>
            <month>Apr</month>
            <day>15</day>
            <issue>2</issue>
            <fpage>CD006931</fpage>
            <pub-id pub-id-type="pmid">19370663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Romunde</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Polito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bertazzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guerriero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pertile</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Results of Full Macular Translocation for Choroidal Neovascularization in Age-Related Macular Degeneration.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>122</volume>
            <issue>7</issue>
            <fpage>1366</fpage>
            <page-range>1366-74</page-range>
            <pub-id pub-id-type="pmid">25881514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martel</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Subretinal pneumatic displacement of subretinal hemorrhage.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>131</volume>
            <issue>12</issue>
            <fpage>1632</fpage>
            <page-range>1632-5</page-range>
            <pub-id pub-id-type="pmid">24337559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shienbaum</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garcia Filho</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Smiddy</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>155</volume>
            <issue>6</issue>
            <fpage>1009</fpage>
            <page-range>1009-13</page-range>
            <pub-id pub-id-type="pmid">23465269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishikova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>AAA</given-names>
              </name>
              <name>
                <surname>Vaideanu-Collins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Isac</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>El-Haig</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Comparison between different techniques for treatment of submacular haemorrhage due to Age-Related Macular Degeneration.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>2621</fpage>
            <page-range>2621-2624</page-range>
            <pub-id pub-id-type="pmid">32993349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Igwe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy for neovascular age-related macular degeneration.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Aug</month>
            <day>26</day>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>CD004004</fpage>
            <pub-id pub-id-type="pmid">32844399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fortmann</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wielechowski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tretiakova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kozarsky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Campochiaro</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration.</article-title>
            <source>Mol Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <day>07</day>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>542</fpage>
            <page-range>542-549</page-range>
            <pub-id pub-id-type="pmid">29292162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r100">
          <label>100</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Quint</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <chapter-title>Angioid Streaks</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">30844178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Choroidal neovascular membrane in intraocular tuberculosis.</article-title>
            <source>GMS Ophthalmol Cases</source>
            <year>2017</year>
            <volume>7</volume>
            <fpage>Doc24</fpage>
            <pub-id pub-id-type="pmid">28944155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal Bevacizumab for Choroidal Neovascular Membrane at the Edge of a Healed Choroidal Tuberculoma.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2018</year>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <page-range>239-241</page-range>
            <pub-id pub-id-type="pmid">27541084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadekar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>An 18-year-old female with unilateral painless vision loss.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2016</year>
            <season>Sep-Dec</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>193</fpage>
            <pub-id pub-id-type="pmid">27843243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chi</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YM</given-names>
              </name>
            </person-group>
            <article-title>Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Feb</month>
            <day>02</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>2735</fpage>
            <pub-id pub-id-type="pmid">33531615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haritoglou</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[PEHCR-Peripheral exudative hemorrhagic chorioretinopathy: Diagnosis and treatment].</article-title>
            <source>Ophthalmologie</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>119</volume>
            <issue>8</issue>
            <fpage>868</fpage>
            <page-range>868-871</page-range>
            <pub-id pub-id-type="pmid">35925329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vandefonteyne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Caujolle</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rosier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Conrath</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quentel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tadayoni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maschi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Le Mer</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aknin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Thariat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baillif</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of peripheral exudative haemorrhagic chorioretinopathy.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>104</volume>
            <issue>6</issue>
            <fpage>874</fpage>
            <page-range>874-878</page-range>
            <pub-id pub-id-type="pmid">31645320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Mashayekhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Peripheral exudative hemorrhagic chorioretinopathy simulating choroidal melanoma in 173 eyes.</article-title>
            <source>Ophthalmology</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>116</volume>
            <issue>3</issue>
            <fpage>529</fpage>
            <page-range>529-35</page-range>
            <pub-id pub-id-type="pmid">19157563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yannuzzi</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Negr&#x000e3;o</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodriguez-Coleman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Slakter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Sorenson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orlock</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Borodoker</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Retinal angiomatous proliferation in age&#x02013;related macular degeneration. 2001.</article-title>
            <source>Retina</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>32 Suppl 1</volume>
            <fpage>416</fpage>
            <page-range>416-34</page-range>
            <pub-id pub-id-type="pmid">22451953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <collab>Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group</collab>
            </person-group>
            <article-title>Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>198</fpage>
            <page-range>198-207</page-range>
            <pub-id pub-id-type="pmid">11176980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <article-title>Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>109</volume>
            <issue>9</issue>
            <fpage>1220</fpage>
            <page-range>1220-31</page-range>
            <pub-id pub-id-type="pmid">1718250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <article-title>Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1993</year>
            <month>Sep</month>
            <volume>111</volume>
            <issue>9</issue>
            <fpage>1200</fpage>
            <page-range>1200-9</page-range>
            <pub-id pub-id-type="pmid">7689827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Natural course of poorly defined choroidal neovascularization associated with macular degeneration.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1988</year>
            <month>Nov</month>
            <volume>106</volume>
            <issue>11</issue>
            <fpage>1537</fpage>
            <page-range>1537-42</page-range>
            <pub-id pub-id-type="pmid">2461191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bressler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Pieramici</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Koester</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>122</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-9</page-range>
            <pub-id pub-id-type="pmid">15006843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanscom</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Diddie</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Early surgical drainage of macular subretinal hemorrhage.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>1722</fpage>
            <page-range>1722-3</page-range>
            <pub-id pub-id-type="pmid">3689195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoeppner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>The risk of fellow eye visual loss with unilateral retinal pigment epithelial tears.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1989</year>
            <month>Dec</month>
            <day>15</day>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>683</fpage>
            <page-range>683-5</page-range>
            <pub-id pub-id-type="pmid">2596548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mangione</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Orav</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Seddon</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Influence of age-related maculopathy on visual functioning and health-related quality of life.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-53</page-range>
            <pub-id pub-id-type="pmid">10482093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Brody</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>The psychosocial impact of macular degeneration.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>116</volume>
            <issue>4</issue>
            <fpage>514</fpage>
            <page-range>514-20</page-range>
            <pub-id pub-id-type="pmid">9565052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <collab>Age-Related Eye Disease Study Research Group</collab>
            <article-title>A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>119</volume>
            <issue>10</issue>
            <fpage>1417</fpage>
            <page-range>1417-36</page-range>
            <pub-id pub-id-type="pmid">11594942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <collab>Age-Related Eye Disease Study 2 Research Group</collab>
            <article-title>Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>May</month>
            <day>15</day>
            <volume>309</volume>
            <issue>19</issue>
            <fpage>2005</fpage>
            <page-range>2005-15</page-range>
            <pub-id pub-id-type="pmid">23644932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Margrain</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Helping blind and partially sighted people to read: the effectiveness of low vision aids.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>84</volume>
            <issue>8</issue>
            <fpage>919</fpage>
            <page-range>919-21</page-range>
            <pub-id pub-id-type="pmid">10906105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133116.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shuttleworth</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Dunlop</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>How effective is an integrated approach to low vision rehabilitation? Two year follow up results from south Devon.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>79</volume>
            <issue>8</issue>
            <fpage>719</fpage>
            <page-range>719-23</page-range>
            <pub-id pub-id-type="pmid">7547780</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
